INTERVENTIONS Healthy volunteers were screened as potential donors and FMT capsules
were generated and stored at −80°C (−112°F). Patients received 15 capsules on 2 consecutive
days and were followed up for symptom resolution and adverse events for up to 6 months.
MAIN OUTCOMES AND MEASURES The primary end points were safety, assessed by adverse
events of grade 2 or above, and clinical resolution of diarrhea with no relapse at 8 weeks.
Secondary end points included improvement in subjective well-being per standardized
questionnaires and daily number of bowel movements.